Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | Company Announcement investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
PSC Partners and PSC Partners Canada, both patient-led non-profit organizations supporting education and research in primary sclerosing cholangitis (PSC), announced today the enrollment of the first patient into the WIND-PSC study. PSC is a rare.